Christopher Yea - Feb 14, 2024 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Role
CHIEF DEVELOPMENT OFFICER
Signature
/s/ Benjamin L. Palleiko, Attorney-in-Fact
Stock symbol
KALV
Transactions as of
Feb 14, 2024
Transactions value $
-$598,661
Form type
4
Date filed
2/16/2024, 04:18 PM
Previous filing
Feb 13, 2024
Next filing
Feb 21, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KALV Common Stock Sale -$599K -39.9K -37.61% $15.01 66.2K Feb 14, 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of performance stock units. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.